CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
CervoMed Inc. (CRVO)
Company Research
Source: GlobeNewswire
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal identified— —Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial— —Trial participants continue to receive neflamapimod during open-label extension— BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (“CervoMed” or the “Company”), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (CDR-SB) or any of its key secondary endpoints – change from baseline in Timed Up and Go (TUG) test, c
Show less
Read more
Impact Snapshot
Event Time:
CRVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVO alerts
High impacting CervoMed Inc. news events
Weekly update
A roundup of the hottest topics
CRVO
News
- CervoMed Inc. (NASDAQ: CRVO) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- CervoMed Inc. (NASDAQ: CRVO) was downgraded by analysts at Brookline Capital Management from a "strong-buy" rating to a "hold" rating.MarketBeat
- CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- CervoMed Inc. (NASDAQ: CRVO) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $65.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- CervoMed Inc. (NASDAQ: CRVO) had its "underweight" rating re-affirmed by analysts at Morgan Stanley.MarketBeat
CRVO
Sec Filings
- 12/10/24 - Form 8-K
- 12/3/24 - Form 8-K
- 11/27/24 - Form 8-K
- CRVO's page on the SEC website